Skip to content

Bronchial asthma (Iraippu) - An oral administration of siddha drug Marutham Pattai kudineer

A Prospective open labelled single arm non-randomized single centric phase II clinical trial to determine the effectiveness of Marutham Pattai Kudineer in the management of Iraippu (Bronchial asthma) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/086015
Enrollment
40
Registered
2025-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: MARUTHAM PATTAI KUDINEER: Dosage:50ml(Twice a day orally before food for 24 days) Control Intervention1: NIL: NIL

Sponsors

Government Siddha Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age: above 18 and below 60 2.Gender: male and female 3.Adults who are diagnosed with bronchial asthma 4.Patients with a clinical symptoms of Iraippu- cough with or without expectoration, recurrent episodes of wheezes, Tightness of chest, shortness of breath. 5.History of allergens, climatic changes 6.Patients who are willing to provide blood for lab investigation.

Exclusion criteria

Exclusion criteria: 1.Age: below 18 and above 60 2.Pulmonary TB 3.Status asthmatics 4.Chronic bronchitis 5.Cardiac failure 6.Renal disease 7.Pregnancy and lactating mothers 8.Autoimmune diseases

Design outcomes

Primary

MeasureTime frame
The outcome is aimed to reduce the clinical symptoms such as shortness of breath, tightness of chest, cough and recurrent of wheezes and to determine the therapeutic efficacy of clinical trial drug MARUTHAM PATTAI KUDINEER. Timepoint: 24 days

Secondary

MeasureTime frame
1.Reduction of ASTHMA CONTROL QUESTIONNAIRE score on comparison with ASTHMA CONTROL QUESTIONNAIRE score prior to treatment 2.Compare the modern parameters such as Absolute eosinophil count and peak flow meter before and after treatment. Timepoint: 24 days

Countries

India

Contacts

Public ContactProf Dr T Komalavalli Alias Mehala

Government Siddha Medical College and Hospital, Palayamkottai

justusantony71@gmail.com9443090849

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026